Rahko is a pioneering company in the field of quantum machine learning, specifically focused on revolutionizing drug discovery. The company leverages advanced quantum computing and machine learning techniques to significantly cut down the cost and time required to discover and develop new drugs. Rahko's clientele includes several multinational pharmaceutical manufacturers and contract research organizations (CROs), indicating its strong foothold in the pharmaceutical and biotech sectors. The company operates in the highly specialized market of quantum chemistry and machine learning for drug discovery. Rahko's business model revolves around providing cutting-edge computational solutions that enhance the precision and speed of drug candidate screening, which are traditionally slow and expensive processes. The company generates revenue through partnerships and collaborations with industry giants like AWS, IBM, Nvidia, and Microsoft, as well as through direct engagements with its pharmaceutical clients. Rahko's innovative approach combines physics-based simulations and data-driven predictions to reliably identify promising drug candidates from a vast array of compounds, thereby addressing a critical bottleneck in the drug discovery pipeline.

Keywords: Quantum computing, Machine learning, Drug discovery, Pharmaceutical, CROs, Quantum chemistry, Computational solutions, AWS, IBM, Nvidia.